



Board and Management Changes

Sydney: 13 February 2014: Animal and human medical products and distribution company Medical Australia Limited (ASX:MLA) today announces a number of changes to its Board and Senior Management.

After leading MLA through a period of significant change Mr Mark Donnison has taken the decision to step down as Managing Director to pursue other business interests. The Board is grateful for Mark's contribution to the Company and wishes him the best for his future endeavours.

Following the completion of the acquisition of MediVet on 10 December 2013, MLA's immediate priority is to finalise the integration of its animal and human healthcare operations. To help achieve this, the Board is pleased to announce the appointment of Darryl Ellis as Chief Operating Officer. Darryl was educated at the Royal Military College – Duntroon, where he developed strong leadership and organisational skills. He has also gained a Master of Business Administration from MGSM, and has completed the Business Management Course at GE's Crontonville management facility in the United States. He has held senior leadership positions at Alcan Australia, CSR, GE Lighting and Assa Abloy.

The MLA Board is confident that through the appointment of an experienced executive in Darryl Ellis, the Company can successfully finalise the MLA/MediVet integration and then focus on implementing a sustainable growth strategy.

MLA is also pleased to announce that it has strengthened its Board with the appointment of Mr Bruce Hancox as Non-Executive Director. Bruce is an experienced company director and executive with strong financial and M&A skills. During his career, he was both an executive and non-executive director of Brierley Investments Limited. In the healthcare sector, Bruce has served as a non-executive director of Neuren Pharmaceuticals Limited since May 2012. He is a director of Windfall (NZ) Trust which recently invested \$2 million into MLA.

Commenting on these board and management changes, MLA's Non-Executive Chairman Gary Lewis said: "MLA is now entering its next growth phase and it is important that we have the right mix of skills at an executive and board level. The acquisition of MediVet and the subsequent capital raising have been company-transforming events, and we are now focused on capitalising on the opportunities that this transaction has brought.

"In the animal healthcare sector, the continued roll-out of the MediVet technology in the United States, and establishing other international distributorships for a range of new products is an immediate priority. In MLA's traditional human healthcare business, there is considerable scope for growth both domestically and internationally, with new OEM agreements, tenders, and product roll-outs being pursued.

"We are also delighted to welcome Bruce Hancox to the Board. He brings considerable experience and skills to MLA given his track record of success in the healthcare sector as well as broader business expertise. We welcome his involvement and recent investment in the company."

ENDS

For more information contact:

Gary Lewis
Non-Executive Chairman Medical Australia Limited
Ph: +61 2 9466 5300

Media please contact: Ben Jarvis, Six Degrees Investor Relations: +61 413 150 448

ABOUT MEDICAL AUSTRALIA LIMITED

Medical Australia Limited (ASX: MLA) is a human and animal healthcare medical company engaged in the manufacture, distribution and sale of a broad range of medical devices used by healthcare facilities and critical care services in global markets. The Company is a leader in Intravenous (IV) Medication Delivery Systems, Surgical Irrigation, Suction and Oxygen Therapy, Safety Sharps Collection and Reuse Prevention and specialised Diagnostic and Laboratory Equipment. Our products are used in three broad areas of healthcare, Human Health; Biological Collection, Processing and Laboratory; and Animal Health. Through the acquisition of MediVet Pty Ltd Medical Australia now has proprietary ownership of technology for regenerative medicine including stem cell therapy for domestic animals and the equine industry. Medical Australia's animal health business is now represented in major countries and regions such as Canada, USA, Great Britain, Continental Europe, Australia and the Asia Pacific Region, including a 60.5% interest in MediVet America LLC.